Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Interviews with the Experts Transplantation & GVHD: What Patients Need to Know

    Why is stem cell transplantation considered a treatment option for many aplastic anemia ... chromosomes that carry a high risk of relapse, or high blast counts, the long-term success is somewhere around 75, maybe 80%. The ...

    Interview last updated 09/30/2014 - 11:07am.

  2. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... or darbepoetin (Aranesp®) work for low red blood cell counts. Romiplostin can be considered a platelet growth factor ... patients receiving romiplostin seemed to have an increased blast percentage, and some of these patients progressed to leukemia. So the ...

    Interview last updated 02/07/2013 - 1:28pm.

  3. Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

    ... This phase II trial studies how well T cell depleted donor peripheral blood stem cell transplant works in ... or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 Acute myeloid leukemia in relapse ...

    Clinical Trial last updated 06/13/2016 - 2:29pm.

  4. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... in case of an infection resulting from low white blood cell counts. How are decisions made about using these two different ... they use – including blood counts, bone marrow blast percentage, and bone marrow chromosome (cytogenetic) analysis. With ...

    Interview last updated 09/22/2014 - 12:25pm.

  5. Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

    ... This phase II trial studies how well selective T cell depletion works in preventing graft-versus-host disease (GVHD) ... or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only) Acute myeloid ...

    Clinical Trial last updated 06/06/2016 - 2:55pm.

  6. Clinical Trials Report for April 2014

    ... anemia who need treatment for significantly low blood cell counts. National Institutes of Health Clinical Center ... with drugs that suppress the immune system or with stem cell transplant. People with SAA who receive these treatments are more likely ... (CML) in chronic phase, accelerated phase or blast crisis; Acute Myelogenous Leukemia (AML); Myelodysplastic Syndrome (MDS); ...

    Page last updated 04/18/2014 - 3:36pm.

  7. Types

    ... Considered the mildest category. MDS is limited to one cell line. There is little dysplasia. Has 3 subtypes: ... treatment of the three primary variables for assessing MDS: blast percentages, cytopenias, and type and degree of chromosomal abnormalities ...

    Topic section last updated 11/14/2016 - 1:11pm.

  8. CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

    ... therapy, who will receive a peripheral blood stem cell transplant . A malignant disease includes the following: Chronic ... Leukemia (CML) in chronic phase, accelerated phase or blast crisis; Acute Myelogenous Leukemia ... this study is to learn more about the effects of CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents and ...

    Clinical Trial last updated 05/03/2016 - 10:47am.

  9. Interviews with the Experts Comorbidities: When Other Medical Conditions Affect MDS Treatment

    ... cases this particular comorbid condition can even help: red cell growth factors like darbepoetin (Aranesp®) or epoetin (Procrit®) can ... specific characteristics, like chromosome results or marrow blast counts. Because most MDS patients are older than age 60, many will ...

    Interview last updated 11/17/2014 - 9:31am.

  10. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... is a single arm pilot study for patients using α/β T cell -depleted PSCT in with alternative donor sources with hematologic ... leukemia Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase. Mixed lineage or biphenotypic ...

    Clinical Trial last updated 06/06/2016 - 3:10pm.